OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin,…
TAIPEI, Taiwan, May 17, 2022 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174), a leader in First-in-Class Cancer therapeutics, today announced that data highlighting ongoing clinical studies targeting Globo H and AKR1C3 in different…